Kugelmeiers
Develops and markets advanced 3D cell culture technologies, including the Sphericalplate 5D platform, for producing uniform, standardized cell spheroids used in research, diagnostics, and regenerative medicine.
- CEO / Founder
- Sandra Kugelmeier
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- Undisclosed
- Latest Round
- Seed
- Key Investors
- Innosuisse Scale-up Coaching Program
Technology & Products
Key Products
Sphericalplate 5D (SP5D); CELLINK Spheroid Kits (via partnership)
Technological Advantage
Proprietary Sphericalplate 5D technology enables high-quality, scalable spheroid production with medical-grade standards, protected by patents and supported by long-term clinical research.
Differentiation
Value Proposition
Enables scalable, high-quality production of standardized cell spheroids for 3D bioprinting and tissue engineering, reducing variability and improving reproducibility in cell-based therapies and research.
How They Differentiate
Focuses on scaffold-free 3D cell culture and standardized spheroid production via Sphericalplate 5D, whereas competitors like CELLINK offer broader bioink and bioprinter portfolios; combines clinical research heritage with scalable platform technology.
Market & Competition
Target Customers
Research institutions, diagnostic labs, regenerative medicine clinics, and biopharmaceutical companies
Industry Verticals
Biotechnology; Pharmaceuticals; Medical Research; Regenerative Medicine
Competitors
CELLINK (BICO Group); Organovo; Prellis Biologics
Growth & Milestones
Growth Metrics
Team grew to 22 specialists as of 2020; planning first human trial in 2020 with four leading European transplant centres.
Major Milestones
Founded in 2015 as spin-off from University of Zurich; Launched Sphericalplate 5D product; Partnership with CELLINK for Spheroid Kits in 2021; Involved in EU ORGANTRANS project for liver tissue 3D printing
Notable Customers
Cellink